Human Recombinant Fibroblast Growth Factor-1 (FGF-1) for Intramyocardial Injection for the Treatment of Coronary Heart Disease.

Trial Profile

Human Recombinant Fibroblast Growth Factor-1 (FGF-1) for Intramyocardial Injection for the Treatment of Coronary Heart Disease.

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Jun 2018

At a glance

  • Drugs Fibroblast growth factor 1 (Primary)
  • Indications Coronary artery disease; Ischaemic heart disorders
  • Focus Therapeutic Use
  • Acronyms ACORD
  • Sponsors CardioVascular BioTherapeutics Inc
  • Most Recent Events

    • 23 Jan 2018 Planned End Date changed from 1 Dec 2015 to 30 Sep 2022.
    • 23 Jan 2018 Planned End Date changed from 1 Dec 2015 to 30 Sep 2022.
    • 23 Jan 2018 Planned primary completion date changed to 30 Sep 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top